All In Biotech

BLA 103172 · Genentech

Activase

Alteplase · Single-Use

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Sep 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1987

Nov 13, 1987

Approved uses

5

Original approval plus efficacy supplements

Registered trials

377

152 Phase 3, 54 recruiting

FAERS reports

15,039

10,406 serious, 3,242 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 20, 2026.

INDICATIONS AND USAGE Cathflo ® Activase ® (Alteplase) is indicated for the restoration of function to central venous access devices as assessed by the ability to withdraw blood.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 4, 2005 Supplement 5071 · Efficacy Label
  • Sep 4, 2001 Supplement 5003 · Efficacy LabelLetter
  • Jun 18, 1996 Supplement 1055 · Efficacy · priority review ReviewLetter
  • Apr 3, 1995 Supplement 1036 · Efficacy · priority review
  • Nov 13, 1987 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
  • ACTIVASE · ALTEPLASE 50MG/VIAL · VIAL, SINGLE-USE · Prescription
  • CATHFLO ACTIVASE · ALTEPLASE 2MG/VIAL · VIAL, · Prescription
  • ACTIVASE · ALTEPLASE 100MG/VIAL · VIAL, SINGLE-USE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Alteplase" as an intervention, any sponsor and status, largest first.

All 377 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event2,541
  • off label use1,883
  • death1,194
  • gingival bleeding1,031
  • cerebral haemorrhage827
  • haemorrhage intracranial741
  • drug ineffective646
  • angioedema631
  • haemorrhage577
  • haemorrhagic transformation stroke441
  • product storage error391
  • nausea372

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200468
200564
200664
200795
2008137
2009241
2010138
2011201
20121,027
2013926
2014422
2015399
2016897
20171,847
2018850
2019395
2020711
2021868
20221,039
2023799
20242,836
2025604
2026411

Recalls

2 FDA enforcement reports for this application.

  • May 20, 2024 · Class II · Terminated

    Lack of Assurance of Sterility: Deformed stoppers observed during filling operations for Cathflo Activase.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated May 21, 2026

    Activase, Injection, 1 KIT in 1 CARTON (50242-085-27) * 100 mL in 1 VIAL, SINGLE-USE * 100 mL in 1 VIAL, SINGLE USE (NDC 50242-085-27). Discontinuation of the 100mg vial configuration

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Activase* (Alteplase*) · HCPCS J2997

2024 spending

$19.2M

Beneficiaries

37,622

58,839 claims

Per beneficiary

$509

2024 ASP limit $90.15 per unit

View as table
YearSpending
2020$56,279,564
2021$51,146,680
2022$39,948,592
2023$27,390,505
2024$19,161,773

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 815 on PubMed

Sponsor: Roche (Genentech) · Also marketed as Cathflo Activase

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.